Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Bio… Read more
Sernova Biotherapeutics Inc (PSH0) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of October 2025: 0.007x
Based on the latest financial reports, Sernova Biotherapeutics Inc (PSH0) has a cash flow conversion efficiency ratio of 0.007x as of October 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-171.13K) by net assets (€-25.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sernova Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Sernova Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sernova Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sernova Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arena Group Holdings Inc
NYSE MKT:AREN
|
-1.170x |
|
CESSATECH A/S DK -20
F:8GN
|
N/A |
|
Onyx Healthcare Inc.
TWO:6569
|
0.018x |
|
Challenger Gold Limited
PINK:CLLEF
|
N/A |
|
Sempio Foods Co
KO:248170
|
0.068x |
|
Jaeren Sparebank
OL:JAREN
|
-0.071x |
|
YAS Co., Ltd.
KQ:255440
|
-0.027x |
|
Solasia Pharma K.K
F:9SO
|
-0.243x |
Annual Cash Flow Conversion Efficiency for Sernova Biotherapeutics Inc (2022–2025)
The table below shows the annual cash flow conversion efficiency of Sernova Biotherapeutics Inc from 2022 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | €-25.08 Million | €-10.91 Million | 0.435x | -70.17% |
| 2024-10-31 | €-12.96 Million | €-18.90 Million | 1.458x | +160.16% |
| 2023-10-31 | €12.51 Million | €-30.34 Million | -2.424x | -700.33% |
| 2022-10-31 | €47.61 Million | €-14.42 Million | -0.303x | -- |